Expert Gives Lowdown On Adverse Event Reporting Bill For Monograph OTCs
This article was originally published in The Rose Sheet
Executive Summary
The compliance of companies newly subject to adverse event reporting and record-keeping requirements will likely be evaluated by FDA on a "performance-oriented basis," said Rick Kingston, PharmD, president and senior clinical toxicologist at SafetyCall International, an adverse event call center